Andrew Young
A5103199313- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
- Viral Infections and Outbreaks Research
- Viral Infections and Vectors
- Animal Virus Infections Studies
- Virology and Viral Diseases
- Travel-related health issues
- Global Health and Surgery
- Respiratory viral infections research
- Influenza Virus Research Studies
- Immunotherapy and Immune Responses
- Vaccine Coverage and Hesitancy
The University of Queensland
2020-2022
London North West Healthcare NHS Trust
2017
Efforts to develop and deploy effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue at pace. Here, we describe rational antigen design through manufacturability vaccine efficacy of a prefusion-stabilised spike (S) protein, Sclamp, in combination with the licensed adjuvant MF59 'MF59C.1' (Seqirus, Parkville, Australia).A panel recombinant Sclamp proteins were produced Chinese hamster ovary screened vitro select lead candidate. The structure this was...
The COVID-19 pandemic response has shown how vaccine platform technologies can be used to rapidly and effectively counteract a novel emerging infectious disease. speed of development for mRNA vector-based vaccines outpaced those subunit vaccines, however, offer advantages in terms safety stability. Here we describe technology, the molecular clamp, application four viruses from divergent taxonomic families: Middle Eastern respiratory syndrome coronavirus (MERS-CoV), Ebola virus (EBOV), Lassa...
Abstract Efforts to develop and deploy effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue at pace with more than 30 candidate now in clinical evaluation. Here we describe the preclinical development of an adjuvanted, prefusion-stabilised Spike (S) protein “Sclamp” subunit vaccine, from rational antigen design through assessing manufacturability vaccine efficacy. In mice, elicits high levels neutralising antibodies epitopes both within outside...
Nipah virus (NiV) and respiratory syncytial (RSV) possess two surface glycoproteins involved in cellular attachment membrane fusion, both of which are potential targets for vaccines. The majority vaccine development is focused on the (G) protein NiV, immunodominant target. In contrast, fusion (F) RSV main target development. Despite this, neutralising epitopes have been described NiV F G, making them alternate design. Through rational design, we developed a strategy applicable to...
Efforts to develop and deploy effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue at pace. Here we describe rational antigen design through manufacturability vaccine efficacy, of a prefusion-stabilised Spike (S) protein, Sclamp. This strategy uses an orthogonal stabilisation approach compared canonical vaccines, in combination with the licensed adjuvant MF59 (Seqirus). In mice, Sclamp elicits high levels neutralising antibodies, as well broadly...
Do you want to work for international non-governmental organisations, be a travel medicine specialist, public health advisor, or tropical doctor in the field? Tropical diplomas expand clinical horizons, develop specialist knowledge, and leave with contacts throughout world. This article looks at four courses. In UK, London Liverpool have world leading faculties superb teaching excellent alumni opportunities. Abroad, will immersed access bedside unique field trips. Peru is cheaper, focus on...